You are here

Results Announced From Phase 3 Trial of Erlotinib and Sorafenib Combination for Liver Cancer

The SEARCH (Sorafenib and Erlotinib, a rAndomized tRial protoCol for the treatment of patients with Hepatocellular carcinoma) trial was an international, multicenter, placebo-controlled phase III study in which 720 patients with advanced liver cancer were randomly assigned to receive either 400 mg of Nexavar twice daily and 150 mg of Tarceva once daily or 400 mg of Nexavar twice daily with matching placebo. The study examined whether the addition of Tarceva to Nexavar could prolong survival compared with Nexavar alone in patients with unresectable HCC. The primary endpoint was overall survival. The safety and tolerability of the treatment combination were generally as expected, based on experience with and use of the two products alone, and no new or unexpected toxicities or changes to the respective product safety profiles were observed. Data from this study will be presented at an upcoming scientific meeting. Nexavar is approved in the U.S. for the treatment of patients with unresectable HCC and for the treatment of patients with advanced renal-cell carcinoma. In preclinical studies, Nexavar was shown to inhibit multiple kinases believed to be involved in both cell proliferation (growth) and angiogenesis (blood supply)––two important processes that enable cancer growth. These kinases include Raf kinase, VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-B, KIT, FLT-3, and RET. Nexavar was jointly developed by Bayer and Onyx. Tarceva is jointly marketed by Astellas and Genentech, a member of the Roche Group. For more information, visit the Onxy Web site.

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs